08:58 AM EDT, 07/17/2025 (MT Newswires) -- DiaMedica Therapeutics ( DMAC ) said Thursday that interim results from Part 1A of its phase-2 study to treat preeclampsia achieved pre-specified safety and efficacy endpoints.

The study is evaluating DM199, which is intended to influence blood pressure regulation and vascular health in preeclampsia treatment.

The study revealed a dose-dependent reduction in both systolic blood pressure and diastolic blood pressure, the company said, adding that data showed DM199 did not cross the placental barrier, which historically has been a safety hurdle in developing treatments for preeclampsia.

The company added that it will now proceed with part 1B of the trial, which will treat an additional up to 30 women with preeclampsia requiring delivery within 72 hours.